CA
SUPN icon

CoreCap Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

CoreCap Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-399
Closed -$20.6K – 3276
2026
Q1 		$20.6K Sell
399
-7,832
-95% -$399K ﹤0.01% 1656
2025
Q4 		$409K Buy
8,231
+7,931
+2,644% +$386K 0.01% 562
2025
Q3 		$14.3K Hold
300
– – ﹤0.01% 1790
2025
Q2 		$9.46K Hold
300
– – ﹤0.01% 1892
2025
Q1 		$9.82K Hold
300
– – ﹤0.01% 1818
2024
Q4 		$10.8K Hold
300
– – ﹤0.01% 1741
2024
Q3 		$9.35K Buy
+300
New +$9.36K ﹤0.01% 1813
2024
Q2 		– Sell
-325
Closed -$11.1K – 2459
2024
Q1 		$11.1K Buy
+325
New +$9.68K ﹤0.01% 1708
2022
Q4 		$11.6K Buy
+325
New +$11.3K ﹤0.01% 1502
2022
Q3 		– Sell
-825
Closed -$24K – 1890
2022
Q2 		$24K Buy
+825
New +$23.6K ﹤0.01% 1185
2022
Q1 		– Sell
-825
Closed -$24K – 1894
2021
Q4 		$24K Buy
+825
New +$25K ﹤0.01% 1272

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

CoreCap Advisors's SUPN Position: Q2 2026 in Review

CoreCap Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 399 shares — an estimated $20.6K sold.

CoreCap Advisors first reported a position in SUPN in Q4 2021 and held it in 11 quarters. The position peaked at $409K in Q4 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • CoreCap Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • CoreCap Advisors sold 399 Supernus Pharmaceuticals shares in Q2 2026, an estimated $20.6K.
  • CoreCap Advisors first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • CoreCap Advisors's Supernus Pharmaceuticals position peaked at $409K in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.